German biotech company Repairon GmbHannounced the completion of a Series A round of financing that will enable further clinical development of its groundbreaking regenerative heart failure therapy. The therapy repairs cardiac function and holds the potential to significantly improve quality of life in patients with advanced heart failure by engrafting lab-engineered cardiac cell sheets to the surface of a damaged ventricle. This approach is currently being tested in a Phase 1/2 clinical study in Germany. Recruitment for the interim analysis of the Phase 2 was completed recently. Preclinical outcomes were published in the journal Nature earlier this year.
Led by Bioventure Management GmbH and strategic co-investor Satorius AG, the financing will enable the transition to a European Phase 3 registration trial and the scaling of GMP (Good Manufacturing Practice) production in collaboration and with know-how from Satorius AG. ErikHoppe, Ph.D., Managing Director of Bioventure, said: “Repairon stands for visionary research with social relevance. The company has the potential to fundamentallychange the treatment of heart failure.” Lothar Germeroth, Ph.D., CEO of Repairon, added that “the engineeredheart muscle offerstheprospectofreversingthecourseofcongestive heart failure andsignificantlyimprovingqualityoflife. Forthefirst time,weseetheopportunityto treatapreviouslyincurableand expensive diseasecausally -withrealglobal benefitsforbothpatients and healthcare systems.”
Theapproach torepairdamaged heart muscle withlab-producedhearttissue sheets is based on more than 30 years of research led by Wolfram-HubertusZimmermann, MD, Ph.D., professor anddirectoroftheInstitute ofPharmacologyand Toxicology at the University Medical Center Goettingen (UMG) in Northern Germany. Repairon, UMG, and the German Center of Cardiovascular Research (DZHK) collaborate closely on the development of this technology.
Highmedical needinadvancedheartfailure:Approximately5%ofthepopulationinGermanysuffers fromchronicheart failureofanyseverity, anditisthethirdmostcommoncauseofdeathinthiscountry. In the US, heart failure represents the most common cause of hospitalization and mortality in the senior population, and over 6 million people are affected. As the heart failure progresses to advancedstages,patients experience weakness with discomfortduring allphysical activitiesandatrest,sometimesevenrequiringconstant bedrest. Fortheseseverely illpatients, theonlytreatmentoptions currentlyavailablearemechanicalpump devices orheart transplantation.
AboutRepairon:RepaironGmbHisaGermanbiotech companybasedinGöttingen,Germany, focusedon developing regenerativecell therapies for cardiac medicine. The company was founded in 2014 based on research by Wolfram-Hubertus Zimmermann, MD, Ph.D.andhisteamattheUniversity Medical Center Goettingen,whohavedeveloped severaltissueengineeringtechnologieswithprovenapplicabilityfororgan repair and drug development. Repairon's lead therapeutic candidate, the human engineered heartmuscle sheet,iscurrently being evaluated intheBioVAT-HFPhase2clinical trialasabiological ventricular support tissue for end-stage heart failure.
AboutBioventure:Foundedin2001,Bioventurehasevolvedfromaspecializedconsultingfirmintoasuccessfulinvestorinlifesciencecompanies.Its focus is on companies with the potential to achieve measurable improvements in healthcare through biomedical innovations. Its investment model is based on exclusive financing vehicles (club deals), allowing wealthy entrepreneurial families and familyofficestoparticipateinpromisingindividualprojects.Bioventure'sactivesupport-fromselection andstrategic development to exit – has led to the distribution of more than €100million to investors. Successful exits with company valuations in the hundreds of millions to billions of euros underscoreBioventure'sexpertiseinscaling high-growthstartups.
https://edge.prnewswire.com/c/img/favicon.png?sn=PH88640&sd=2025-10-02
View original content:https://www.prnewswire.com/news-releases/groundbreaking-therapy-for-advanced-heart-failure-repairon-completes-series-a-financing-to-expand-the-clinical-development-of-its-regenerative-heart-therapy-302573384.html
SOURCE Repairon GmbH
https://rt.newswire.ca/rt.gif?NewsItemId=PH88640&Transmission_Id=202510020836PR_NEWS_USPR_____PH88640&DateId=20251002